However, recent Mendelian randomization studies concerning lipid-lowering drug target genes and their relationship with NAFLD have shown that targets such as HMG-CoA reductase, PCSK9, Apolipoprotein B100, LDL Receptor, and ANGPTL3 do not positively influence the outcomes of NAFLD or the risk of cardiovascular diseases [9]. This evidence concerns the gene PCSK9 and metabolic dysfunction-associated steatotic liver disease.